We're Not Worried About Intervacc's (STO:IVACC) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Swedish (OMX) Biotech Industry Analysis
UpdatedMay 14, 2022
DataAggregated Company Financials
Companies71
- 7D2.5%
- 3M-16.2%
- 1Y-16.2%
- YTD-27.9%
The Biotech industry is up 2.5% in the last week, with Swedish Orphan Biovitrum up 4.8%. In the same time, BioGaia was down 8.1%. In the past year, the industry is down 16%. Looking forward, earnings are forecast to grow by 36% annually.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Sat, 14 May 2022 | kr146.6b | kr21.4b | -kr3,333,951,596.00 | 45.3x |
| Mon, 11 Apr 2022 | kr176.5b | kr19.7b | -kr3,199,792,054.00 | 51.1x |
| Wed, 09 Mar 2022 | kr145.5b | kr19.6b | -kr3,014,129,042.00 | 46.7x |
| Fri, 04 Feb 2022 | kr171.5b | kr19.1b | -kr2,253,351,866.00 | 51.8x |
| Sun, 02 Jan 2022 | kr200.6b | kr19.1b | -kr2,003,719,849.00 | 53.3x |
| Tue, 30 Nov 2021 | kr201.1b | kr19.0b | -kr1,980,520,932.00 | 53x |
| Thu, 28 Oct 2021 | kr200.3b | kr18.9b | -kr1,187,343,383.00 | 54.4x |
| Sat, 25 Sep 2021 | kr212.4b | kr18.1b | -kr1,339,284,004.00 | 51.8x |
| Mon, 23 Aug 2021 | kr193.7b | kr18.1b | -kr1,175,418,285.95 | 54.5x |
| Sat, 10 Jul 2021 | kr170.4b | kr18.1b | -kr1,169,741,285.95 | 58.6x |
| Fri, 02 Apr 2021 | kr148.3b | kr17.8b | -kr1,318,179,930.10 | 43.9x |
| Mon, 04 Jan 2021 | kr162.3b | kr18.7b | -kr825,138,964.85 | 51.9x |
| Thu, 08 Oct 2020 | kr170.0b | kr19.1b | -kr478,713,101.07 | 52.1x |
| Wed, 01 Jul 2020 | kr145.8b | kr19.1b | kr28.3m | 42.2x |
| Sat, 04 Apr 2020 | kr106.0b | kr19.3b | kr512.8m | 39.4x |
| Tue, 07 Jan 2020 | kr115.4b | kr17.9b | kr501.4m | 39.3x |
| Mon, 30 Sep 2019 | kr108.8b | kr16.0b | kr194.9m | 39.1x |
| Thu, 04 Jul 2019 | kr122.6b | kr15.4b | kr616.5m | 36.3x |
Median PE Ratio
35.4x
Current Industry PE
- Investors are relatively neutral on the industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 45.7x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 14% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | -1.98% | |
| Healthcare | 2.52% | |
| Biotech | 2.54% | |
| Biotech | 2.54% | |
Industry PE
- Investors are most optimistic about the Biotech industry, which is trading close to its 3-year average PE ratio of 45.7x.
- Analysts are expecting annual earnings growth of 36%, which is higher than its past year's earnings decline of 7.3% per year.
Forecasted Growth
- Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 36% over the next 5 years.
- This is better than its past earnings decline of 7.3% per year.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SOBI Swedish Orphan Biovitrum | kr210.60 | 4.8% +kr2.9b | 44.8% | PS24.6x | |
| VITR Vitrolife | kr231.60 | 7.1% +kr2.1b | -25.0% | PS102.8x | |
| PROB Probi | kr296.50 | 6.3% +kr199.4m | -38.6% | PS45.3x | |
| BIOA B BioArctic | kr74.35 | 2.3% +kr145.3m | -4.3% | PS308.9x | |
| IVACC Intervacc | kr32.00 | 5.5% +kr84.3m | -56.4% | PS179.9x |